Inotuzumab-ozogamicin/BlinatumomabNo response: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2021年 / 1864卷 / 1期

关键词：

D O I：

10.1007/s40278-021-99125-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：195 / 195

相关论文

共 50 条

[1] Inotuzumab-ozogamicin/olverembatinibVein obstruction syndrome: case report
Reactions Weekly, 2024, 2027 (1) : 239 - 239
[2] Inotuzumab-ozogamicin/methotrexate/pegaspargaseVarious toxicities: case report
Reactions Weekly, 2020, 1814 (1) : 186 - 186
[3] Inotuzumab-ozogamicin/cyclophosphamide/fludarabineVarious toxicities: case report
Reactions Weekly, 2023, 1983 (1) : 238 - 238
[4] Inotuzumab-ozogamicin/methotrexate/vincristineVarious toxicities: case report
Reactions Weekly, 2023, 1972 (1) : 188 - 188
[5] Cytarabine/inotuzumab-ozogamicin/nelarabineLack of efficacy and rhabdomyolysis: case report
Reactions Weekly, 2022, 1915 (1) : 159 - 159
[6] Inotuzumab-ozogamicin toxicityInotuzumab-ozogamicin toxicity leading to death: case report
Reactions Weekly, 2022, 1888 (1) : 204 - 204
[7] Inotuzumab-ozogamicin/rituximabLack of efficacy
Reactions Weekly, 2024, 2001 (1) : 178 - 178
[8] Inotuzumab-ozogamicin, blinatumomab and imatinibLack of efficacy: 3 case reports
Reactions Weekly, 2021, 1882 (1) : 251 - 251
[9] Dasatinib/inotuzumab-ozogamicin/ruxolitinibLack of efficacy: 2 case reports
Reactions Weekly, 2023, 1938 (1) : 491 - 491
[10] Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies
Shor, Boris
Gerber, Hans-Peter
Sapra, Puja
MOLECULAR IMMUNOLOGY, 2015, 67 (02) : 107 - 116

← 1 2 3 4 5 →